Janssen Pharmaceutica N.V. Clinical Trial
Janssen Pharmaceutica N.V.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
31
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
0
PubMed author-name match
Trials
Studies that name Janssen Pharmaceutica N.V. Clinical Trial as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:31 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT01533285 · Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder PatientsJanssen Pharmaceutica N.V., Belgium · completed · Major Depressive Disorder · study director
- N/ANCT01524445 · Retrospective Survey of Re-treatment With BortezomibJanssen Pharmaceutica N.V., Belgium · completed · Hematological Cancer, Multiple Myeloma · study director
- N/ANCT01241396 · A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any ProcedureJanssen Pharmaceutica N.V., Belgium · completed · Multiple Myeloma · study director
- Early Ph1NCT01186471 · The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic PatientsJanssen Pharmaceutica N.V., Belgium · completed · Schizophrenia, Cognition Disorders · study director
- Early Ph1NCT01181934 · The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.Janssen Pharmaceutica N.V., Belgium · completed · Schizophrenia, Cognition Disorders · study director
- Ph1NCT01137799 · The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic PatientsJanssen Pharmaceutica N.V., Belgium · terminated · Schizophrenia, Alzheimer's Disease, Cognition Disorders · study director
- N/ANCT00696813 · Observational Study to Assess Outcomes During Antipsychotic Treatment With Paliperidone ER or Other Oral AntipsychoticsJanssen-Cilag International NV · completed · Schizophrenia · study director
- Ph4NCT00524160 · A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, in Patients With Rheumatoid Arthritis or OsteoarthritisJanssen Pharmaceutica N.V., Belgium · completed · Arthritis, Osteoarthritis, Rheumatoid Arthritis · study director
- N/ANCT00458367 · RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical PracticeJanssen Pharmaceutica N.V., Belgium · completed · Schizophrenia, Psychotic Disorders, Schizoaffective Disorder · study director
- Ph3NCT00391222 · A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I DisorderJanssen Pharmaceutica N.V., Belgium · completed · Bipolar Disorder · study director
- Ph4NCT00369239 · Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of PsychosisJanssen Pharmaceutica N.V., Belgium · completed · Schizophrenia, Psychotic Disorders, Schizoaffective Disorder · study director
- Ph4NCT00338000 · EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal FailureJanssen Pharmaceutica N.V., Belgium · completed · Chronic Renal Failure · study director
- N/ANCT00291421 · A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's DiseaseJanssen Pharmaceutica N.V., Belgium · completed · Alzheimer Disease, Dementia, Nervous System Diseases · study director
- Ph3NCT00271414 · A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief TherapyJanssen Pharmaceutica N.V., Belgium · completed · Chronic Pain · study director
- Ph3NCT00266552 · A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental RetardationJanssen Pharmaceutica N.V., Belgium · completed · Conduct Disorder, Disruptive Behavior Disorder, Oppositional Defiant Disorder · study director
- Ph4NCT00261482 · Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.Janssen Pharmaceutica N.V., Belgium · completed · Contraception, Female Contraception · study director
- Ph3NCT00261495 · A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.Janssen Pharmaceutica N.V., Belgium · completed · Pain · study director
- Ph3NCT00250367 · A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.Janssen Pharmaceutica N.V., Belgium · completed · Bipolar Disorder, Manic Disorder · study director
- Ph3NCT00250354 · A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental RetardationJanssen Pharmaceutica N.V., Belgium · completed · Conduct Disorder, Oppositional Defiant Disorder, Disruptive Behavior Disorder · study director
- Ph3NCT00249223 · A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic SchizophreniaJanssen Pharmaceutica N.V., Belgium · completed · Schizophrenia, Psychotic Disorders · study director
- Ph3NCT00249145 · A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With DementiaJanssen Pharmaceutica N.V., Belgium · completed · Dementia, Alzheimer Disease, Dementia, Vascular · study director
- Ph4NCT00249171 · A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic PatientsJanssen Pharmaceutica N.V., Belgium · completed · Schizophrenia, Psychotic Disorders, Emergency Treatment · study director
- Ph3NCT00246220 · A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.Janssen Pharmaceutica N.V., Belgium · completed · Attention Deficit Disorder With Hyperactivity · study director
- Ph3NCT00236392 · A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)Janssen Pharmaceutica N.V., Belgium · completed · Gastroesophageal Reflux, Heartburn · study director
- Ph4NCT00236366 · A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, Compared With Placebo in Patients With OsteoarthritisJanssen Pharmaceutica N.V., Belgium · completed · Osteoarthritis, Arthritis · study director
- Ph3NCT00216606 · The Effectiveness and Safety of Topiramate on Prevention of Chronic MigraineJanssen Pharmaceutica N.V., Belgium · completed · Migraine · study director
- Ph4NCT00216671 · Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute EpisodeJanssen Pharmaceutica N.V., Belgium · completed · Schizophrenia · study director
- Ph3NCT00216593 · Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled StudyJanssen Pharmaceutica N.V., Belgium · completed · Dementia, Alzheimer Disease · study director
- Ph3NCT00216619 · The Prolonged Use of Topiramate for Preventing Migraine HeadachesJanssen Pharmaceutica N.V., Belgium · completed · Migraine · study director
- Ph3NCT00216580 · A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset PsychosisJanssen Pharmaceutica N.V., Belgium · completed · Schizophrenia · study director
- Ph4NCT00216632 · A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)Janssen Pharmaceutica N.V., Belgium · completed · Schizophrenia, Psychotic Disorders · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.